Decreased complement C3 levels are associated with poor prognosis in patients with COVID-19: A retrospective cohort study

Shilin Fang,Haizhou Wang,Li Lu,Yifan Jia,Zhongyuan Xia
DOI: https://doi.org/10.1016/j.intimp.2020.107070
IF: 5.714
2020-12-01
International Immunopharmacology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objectives</h3><p>To describe the humoral immune feature of patients with coronavirus disease 2019 (COVID-19).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>The levels of total immunoglobulins (IgG, IgM, IgA, and IgE), complement (C3, C4) results were retrospectively analyzed in COVID-19 patients. Univariable and multivariable logistic regression were performed to explore the risk factors associated with the in-hospital death.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Result</h3><p>A total of 236 patients were enrolled in this study, of which 169 were transferred to another institution or discharged (survival group) and 67 died in hospital (non-survival group). Compared with survivors, the levels of IgA and IgE in non-survivors increased significantly, and level of complement C3 decreased. Non-survivors also showed higher incidence of chest tightness, breath shortness and dyspnoea; higher levels of inflammatory indicators, leukocytes and neutrophils; and low levels of lymphocyte subsets. Multivariable regression showed increasing odds of in-hospital death associated with older age (HR: 1.099; 95%CI: 1.057–1.143; <em>p</em> &lt; 0.0001), d-dimer greater (HR: 1.294; 95%CI: 1.138–1.473; <em>p</em> &lt; 0.0001) and decreased complement C3 level (HR: 0.073; 95%CI: 0.007–0.722; <em>p</em> = 0.025) on admission. Finally, in survival COVID-19 patients whose humoral immunity was re-examined, C3 levels tended to increase, while in non-survivors it decreased.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>Low level of complement C3 may be an alert to the admitted COVID-19 patients with additional management. Inhibition of the complement pathway might be an effective therapeutic to COVID-19 patients.</p>
pharmacology & pharmacy,immunology
What problem does this paper attempt to address?